Characteristics Year of SHAS interview{ 2000 2001 2002 2003 2004 Sex Male Female Race/Ethnicity White, non-Hispanic Black, non-Hispanic Hispanic Other Age group (years) 18–29 30–39 40–49 $50 Employed Yes No Current annual income ,$10,000 $10,000–20,000 $$20,000 Unknown or refused to answer Education ,High school/General Equivalency Diploma (GED) High school/GED .High school/GED Medical insurance Yes No Region of residence{ Northeast South Midwest West Current living situation Alone With partner, family, or friend In a medical facility In shelter Other6 45 (14.7) 82 (26.9) 93 (30.5) 60 (19.7) 25 (8.2) 240 (78.7) 65 (21.3) 67 (22.0) 179 (58.7) 46 (15.1) 13 (4.3) 38 (12.5) 112 (40.0) 113 (37.0) 32 (10.5) 92 (30.2) 213 (69.8) 161 (57.8) 53 (17.4) 70 (22.9) 21 (6.9) 94 (30.8) 95 (31.1) 116 (38.0) 240 (78.7) 65 (21.3) 25 (8.2) 155 (50.8) 48 (15.7) 77 (25.2) 100 (32.8) 172 (56.4) 10 (3.3) 15 (4.9) 8 (2.6) 111 (8.2) 407 (29.9) 411 (30.2) 333 (24.5) 99 (7.3) 1040 (76.4) 321 (23.6) 273 (20.1) 762 (56.6) 269 (19.8) 57 (4.7) 126 (9.3) 498 (36.6) 550 (40.4) 187 (13.7) 383 (28.1) 978 (71.9) 666 (48.9) 265 (19.5) 322 (23.7) 108 (7.9) 446 (32.8) 433 (31.8) 482 (35.4) 1,075 (79.0) 286 (21.0) 73 (5.4) 728 (53.5) 212 (15.6) 348 (25.6) 403 (29.6) 837 (61.5) 42 (3.1) 47 (3.4) 32 (2.3) Table 1. Characteristics of 1,666 persons with HIV infection prescribed primary prophylaxis against Pneumocystis jirovecii pneumonia (PCP), by nonadherence to prophylaxis – Supplement to HIV/AIDS Surveillance (SHAS) project, 2000–2004. Table 1. cont. Characteristics Primary PCP Prophylaxis Nonadherent* N = 305 n (%) Adherent* N = 1,361 n (%) PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e5002 PCP Prophylaxis Nonadherence Primary PCP Prophylaxis Nonadherent* N = 305 n (%) Adherent* N = 1,361 n (%) Illicit drug use in past year1{ No 142 (46.6) Marijuana only 54 (17.7) Non-injection drugs other than marijuana 81 (26.6) Injection drug use 28 (9.2) Risk for alcoholism||{ Yes 103 (33.8) No 202 (66.2) Mental health described as not good $1 day during the last month{ Yes 232 (76.1) No 73 (23.9) Recent CD4 count (cells/mL){ ,200 160 (52.5) $200 77 (25.2) Unknown/missing 68 (22.3) Viral load (copies/mL){ #5000 108 (35.4) .5,000 74 (24.3) Unknown/missing 123 (40.3) Current PCP medication prescribed Trimethoprim-sulfamethoxazole 243 (79.7) Dapsone 37 (12.1) Other/unknown 25 (8.2) Antiretroviral therapy (ART) in the past month{ On ART, always adherent 59 (19.3) On ART, usually adherent 125 (41.0) On ART, sometimes, rarely, or never 59 (19.3) adherent On ART, unknown or missing information 20 (6.6) about adherence Not on ART 42 (13.8) Total number of pills prescribed for daily use 1–3 87 (28.5) 4–5 120 (39.3) $6 98 (32.1) Recruitment type Facility-based 192 (62.9) Population-based 113 (37.0) 899 (66.0) 179 (13.1) 233 (17.1) 50 (3.7) 328 (24.1) 1.033 (75.9) 821 (60.3) 540 (39.7) 536 (39.4) 393 (28.9) 432 (31.7) 525 (38.6) 240 (17.6) 596 (43.8) 1078 (79.2) 169 (12.4) 114 (8.4) 910 (66.9) 194 (14.2) 44 (3.2) 104 (7.6) 109 (8.0) 371 (27.3) 515 (37.8) 475 (34.9) 894 (65.7) 467 (34.3) *Column percentages may not total 100% because of rounding. {P-value ,0.05 when comparing persons nonadherent with those adherent to PCP prophylaxis. {Regions defined by U.S. Census Bureau; for SHAS sites included in this analysis, Northeast comprises NJ, CT, and PA; South comprises GA, MD, FL, SC, DE, and TX; Midwest comprises IL, KS, MI, and MN; and West comprises AZ, CA, CO, NM, and WA. 6Other responses included correctional institution, refused to answer, and other responses which did not fit into the listed response categories. 1Categories are mutually exclusive. ||Defined as answering yes to at least 2 of the CAGE screening questions and reporting alcohol use in the past year. doi:10.1371/journal.pone.0005002.t001